TokyoTokyo Mon - Fri 10:00-18:00 +81 (368) 662-975
info@mountequitygroup.com

Rubius Therapeutics Appoints Jim Jogerst as Chief Business

Mount Equity Group Tokyo, Japan > News > Business > Rubius Therapeutics Appoints Jim Jogerst as Chief Business

CAMBRIDGE Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Jim Jogerst as chief business officer. He will oversee business development strategy and execution, including strategic partnerships, collaborations and alliances that align with Rubius’ overall corporate strategy.

“Jim brings more than 20 years of experience in mergers and acquisitions, business development and licensing transactions, valued in excess of $20 billion,” said Pablo J. Cagnoni, M.D., president and chief executive officer at Rubius Therapeutics. “As we continue to grow our promising pipeline of Red Cell Therapeutics, Jim’s expertise and strong track…

Read more…